Last reviewed · How we verify
rilpivirina + emtricitabina + tenofovir
This combination inhibits HIV reverse transcriptase through three complementary mechanisms: rilpivirina as a non-nucleoside reverse transcriptase inhibitor (NNRTI) and emtricitabina and tenofovir as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs).
This combination inhibits HIV reverse transcriptase through three complementary mechanisms: rilpivirina as a non-nucleoside reverse transcriptase inhibitor (NNRTI) and emtricitabina and tenofovir as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). Used for HIV-1 infection in treatment-naïve adults, HIV-1 infection in treatment-experienced patients (with specific resistance profiles).
At a glance
| Generic name | rilpivirina + emtricitabina + tenofovir |
|---|---|
| Also known as | eviplera |
| Sponsor | Hospital Universitari Vall d'Hebron Research Institute |
| Drug class | Antiretroviral combination therapy (NNRTI + 2 NRTIs) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Rilpivirina binds directly to HIV reverse transcriptase and blocks its catalytic activity. Emtricitabina and tenofovir are nucleoside analogs that are incorporated into the growing viral DNA chain, causing chain termination and preventing viral replication. Together, these three agents target reverse transcriptase through different mechanisms to suppress HIV replication.
Approved indications
- HIV-1 infection in treatment-naïve adults
- HIV-1 infection in treatment-experienced patients (with specific resistance profiles)
Common side effects
- Rash
- Nausea
- Diarrhea
- Headache
- Elevated liver enzymes
- Renal impairment (tenofovir-related)
- Bone density loss
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: